The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: A pilot study

International Journal of STD and AIDS

Volumn 14, Issue 11, 2003, Pages 732-736

  Jayaweera, D T ^a   Scerpella, E ^a   Robinson, M ^b   Rode, R ^b   Campo, R ^a   Rodriguez, A ^a   Asthana, D ^a   Tanner, T ^a   Kolber, M A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Efficacy; Indinavir; Ritonavir; Safety

Indexed keywords

CD4 ANTIGEN; CHOLESTEROL; INDINAVIR; RITONAVIR; TRIACYLGLYCEROL;

ARTICLE; CITY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HAITI; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MINORITY GROUP; NAUSEA; NEGRO; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RASH; T LYMPHOCYTE; VIRUS LOAD; VOMITING;

AFRICAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HAITI; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LOGISTIC MODELS; MALE; PATIENT COMPLIANCE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RITONAVIR; UNITED STATES; URBAN POPULATION; VIRAL LOAD;

EID: 0242690233     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/09564620360719750     Document Type: Article

References (24)

1. Palella FJ, Delaney KM, Moorman AC, et al. Decline in morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
2. www.HIVatis.org
3. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by co administration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60
4. Gisolf EH, Jurriaans S, Pelgrom J, et al. The effect of treatment intensification in HIV-1-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000;14:405-13
5. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30
6. Chesney MA, Morin M, Sherr L. Adherence to HIV-1 combination therapy. Soc Sci Med 2000;50:1599-605
7. Sipler AM, Cross JT, Lane DR, et al. The relationship between literacy, race and adherence to patient anti-retroviral therapies. In: 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill, Abstract 108, 1999
8. Shulman N, Cutter G, Daugherty R, et al. Correlates of attendance and compliance in the hypertension detection and follow-up program. Control Clin Trials 1982;3:13-27
9. Dobscha SK, Delucchi K, Young ML. Adherence with referrals for outpatient follow-up from a VA psychiatric emergency room. Community Ment Health J 1999;35:451-8
10. Bond W, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991;48:1978-88
11. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV-1 infection. Ann Intern Med 2000;133:21-30
12. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73
13. Staszewski S, Keizer P, Montaner J, et al. Abacavir-lamivudine- zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-1-infected adults. A randomized equivalence trial. JAMA 2001;285:1155-63
14. Squire K, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV-1 infection: selection of thymedine analog regimen therapy (START 1). AIDS 2000;14:1591-600
15. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1-1 patients: a prospective cohort study. Swiss HIV-1 Cohort Study. Lancet 1999;353:863-8
16. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7
17. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-53
18. Babudieri S, Aceti A. Directly observed therapy to treat HIV-1 infection in prisoners. JAMA 2000;284:179
19. Fischl M, Rodriguez A, Scerpella E, et al. Impact of directly observed therapy on outcomes in HIV-1 clinical trials. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco: Abstract 71, 2000
20. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21
21. Kolber MA, Gabr AH, De La Rosa A, et al. Genotype analysis of plasma HIV-1-1 RNA after influenza vaccination of patients previously undetectable viral loads. AIDS 2002;16:537-42
22. Staszewski S, Miller V, Sabin CA, et al. Virological response to protease inhibitor therapy in HIV-1 clinic cohort. AIDS 1999;13:367-73
23. Thiebaut R, Morlat P, Jacqmin-Gedda H, et al. Clinical progression of HIV-1 infection according to the viral responses during the first year of antiretroviral treatment. AIDS 2000;14:971-8
24. Lepri AC, Miller V, Phillips A, et al. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-HAART viral load and the weeks 4-8 viral load. AIDS 2001;15:47-54